Medivir’s series A shares to be converted into series B shares
Stockholm, Sweden — Medivir AB (publ) (“Medivir” or the “Company”) (Nasdaq Stockholm: MVIR) today announces that the holders of series A shares have notified the Company that they will convert all their series A shares in Medivir to series B shares. The conversion will be completed as soon as possible following the Extraordinary General Meeting in Medivir to be held on 26 January 2018.
Following the conversion, there will no longer be any series A shares outstanding in Medivir. The total number of shares in Medivir will not be affected, but all outstanding shares will be series B shares. Since each series A share carries ten votes and each series B share one vote, the conversion of the series A shares (in total 474,769) will imply that the total number of votes in Medivir decreases from 24,591,898 to 20,318,977. Since the respective voting power of the largest holders of series A shares (Bo Öberg and Nils Gunnar Johansson) falls below the five percent threshold, they will make a separate notification (flagging) thereof.
The holders of series A shares Bo Öberg and Nils Gunnar Johansson comment:
“The strong voting power of series A shares has been important for a relatively long period of time to give Medivir stability. Medivir is now in the fortunate position of having a very strong clinical portfolio and an impressive creation of new patents in oncology. Therefore, the series A shares are no longer needed.”
For further information, please contact:
Christine Lind, CEO Medivir AB, phone: +46 (0)8 5468 3100
Anders Lundin, CFO Medivir AB, phone: +46 (0)73 125 1453
This is information that Medivir AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 8.15 CET on 2 January 2018.
About Medivir
Medivir is a research-based pharmaceutical company with a focus on oncology. We have a leading competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet great unmet medical needs. Medivir is listed on the Nasdaq Stockholm Mid Cap List.
Tags: